Successful treatment of immune thrombocytopenic purpura (ITP) with the thrombopoietin-mimetic Romiplostim
John Meletis, Aikaterini Katsandris, Sophia D. Raptis, Marina Mantzourani
Med Sci Monit 2010; 16(8): CS100-102
Available online: 2010-08-01
Background: Romiplostim is a second-generation thrombopoietic receptor agonist that exerts its therapeutic effect by stimulating megakaryopoiesis.
Case Report: We report a patient with immune thrombocytopenic purpura refractory to other therapies including splenectomy, which was successfully managed with romiplostim. More specifically, the patient’s platelet count showed a 3-fold increase within 7 days following the first dose of romiplostim (from 33×109/l to 96×109/l).
Conclusions: Romiplostin is a new trombopoietin peptide mimetic drug, which seems to be very effective for the management of refractory chronic ITP in adults.
Keywords: Thrombopoietin - therapeutic use, Recombinant Fusion Proteins - therapeutic use, Receptors, Fc - therapeutic use, Purpura, Thrombocytopenic, Idiopathic - drug therapy, Adult